With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that provides pipeline-in-a-product potential addressing a goal that has scientific and regulatory validation from a not too long ago authorized Novartis drug. Vidya’s molecule is a next-generation drug that might have benefits over Novartis’s capsule.
The publish Processa Acquisition Lands Immunology Drug That May Rival a New Novartis Product appeared first on MedCity Information.
